Understand the source comparison
Peptide Research News December 2026 Roundup: Research Trends vs Clinical Translation
CNS-Active Peptides Stanford, Johns Hopkins, UC San Diego Lipidated Dihexa analogues: 4.2× BBB penetration; cerebrolysin mechanism mapped; P21 cognitive improvement in MCI Phase 2 (P21 complete); Phase 1 (lipidated Dihexa analogues) BBB penetration was the pri
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CNS-Active Peptides
- Stanford, Johns Hopkins, UC San Diego
- Lipidated Dihexa analogues: 4.2× BBB penetration; cerebrolysin mechanism mapped; P21 cognitive improvement in MCI
- Phase 2 (P21 complete); Phase 1 (lipidated Dihexa analogues)
- BBB penetration was the primary barrier to CNS peptide translation. Stanford's lipidation approach is the first reproducible solution that maintains pharmacological activity
- Metabolic Dual Agonists
- Eli Lilly (survodutide), Hanmi Pharma (mazdutide)
- Survodutide: 18.7% weight loss, 91% fat mass; mazdutide: 6.8-day half-life, weekly dosing confirmed
- Phase 3 (survodutide complete); Phase 2b (mazdutide recruiting)
- Dual agonism preserves lean mass during weight loss. This addresses the primary limitation of single-target GLP-1 protocols where muscle catabolism compounds metabolic slowdown
- Immune Modulation
- Clinical Immunology Consortium (thymalin), Karolinska Institute (KPV)
- Thymalin: 34% increase in thymic output biomarkers; KPV: 62% reduction in NF-κB activation
- Phase 3 complete (thymalin); preclinical (KPV)
- Thymalin's immunosenescence reversal is statistically significant but modest. Real-world application will depend on whether the effect compounds over multi-year administration
- Regenerative Peptides
- Moscow State (cartalax), University of Tokyo (MK-677)
- Cartalax: 47% reduction in cartilage degradation; MK-677: +1.8 kg lean mass in sarcopenia trial
- Preclinical (cartalax); Phase 2 complete (MK-677)
- MK-677's growth hormone secretagogue mechanism avoids exogenous peptide administration. Regulatory pathway clearer than recombinant GH protocols